Stockscreener 앱 받기
2.15
1.90%
0.04
시장 영업 전:
2.10
-0.05
-2.33%
전일 마감가:
$2.11
열려 있는:
$2.12
하루 거래량:
121.98K
Relative Volume:
0.63
시가총액:
$30.84M
수익:
-
순이익/손실:
$-26.26M
주가수익비율:
-0.3145
EPS:
-6.8353
순현금흐름:
$-26.82M
1주 성능:
+27.22%
1개월 성능:
+35.22%
6개월 성능:
-56.78%
1년 성능:
-37.23%
1일 변동 폭
$2.06
$2.16
1주일 범위
$1.64
$2.18
52주 변동 폭
$1.20
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
명칭
Tempest Therapeutics Inc
전화
415-798-8589
주소
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
2.15 | 30.84M | 0 | -26.26M | -26.82M | -6.8353 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-08 | 개시 | Jefferies | Buy |
Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스
MSN Money - MSN
TPST Q1'26 Earnings: revenue estimate is 0 USD - TradingView
After six complete responses, Tempest brings updated CAR-T data to Dublin - Stock Titan
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - Sahm
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN
Tempest Therapeutics stock falls after $4.25 million direct offering - MSN
Tempest achieves manufacturing milestone for CAR-T therapy By Investing.com - Investing.com India
Tempest Therapeutics provides update on development of TPST-2003 - TipRanks
Tempest Therapeutics (TPST) Advances Dual-Targeting CAR-T Therap - GuruFocus
Tempest achieves manufacturing milestone for CAR-T therapy - Investing.com
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - GlobeNewswire
Tempest Therapeutics (TPST) Stock: Why Spinoff Value (Tick Down) 2026-04-20Trending Buy Opportunities - Cổng thông tin điện tử tỉnh Lào Cai
TPST Forecast, Price Target & Analyst Ratings | TEMPEST THERAPEUTICS INC (NASDAQ:TPST) - ChartMill
Tempest Therapeutics names Andrew Fang head of business development By Investing.com - Investing.com India
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - Bitget
Tempest Therapeutics names Andrew Fang head of business development - Investing.com
Tempest Appoints Andrew Fang, Ph.D., as Head of Business - GlobeNewswire
Tempest Therapeutics(TPST) Stock Options Chain | Quotes & News - Moomoo
Form S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments - ADVFN
Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers - Stock Titan
Buyout Rumor: What is Stran Company Incs revenue forecast2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn
New Strong Buy Stocks for April 10th - The Globe and Mail
Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29%Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La
[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan
Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors - marketscreener.com
Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan
Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64 - Stock Titan
Versant funds report lower Tempest Therapeutics (TPST) ownership levels - Stock Titan
Biopharmaceutical company Tempest Therapeutics Inc (TPST) recently filed a prospectus with the U.S. Securities and Exchange Commission, planning to issue up to approximately 2.8 million common shares through resale, including related warrants. - Bitget
According to a filing submitted to the US Securities and Exchange Commission (SEC), Tempest Therapeutics Inc. will not receive any proceeds from the sale of the company's shares by selling shareholders. - Bitget
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST) - The Globe and Mail
Tempest Therapeutics | UPLOAD: Others - Moomoo
H.C. Wainwright Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
TPST Q4'25 Earnings: EPS estimate is (0.62) USD - TradingView — Track All Markets
According to the latest filing disclosed by the SEC, existing shareholders of biopharmaceutical company Tempest Therapeutics Inc. plan to resell up to 8.27 million shares of the company's common stock. - Bitget
Scienture Holdings Inc (MEDS) Reports FY2025 Earnings - AlphaStreet
Tempest Reports Year End 2025 Financial Results and Provides Business Update - bitget.com
Tempest reports year end 2025 financial results and provides business update - marketscreener.com
Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings - AlphaStreet
Tempest Therapeutics 2026 10-K: Pipeline Overview, CAR-T & Small Molecule Oncology Strategies, Key Partnerships, and Competitive Position - Minichart
Tempest's new CEO arrives as six myeloma patients hit complete response - Stock Titan
Tempest Therapeutics Inc (TPST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):